• 29 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Latest
    Open Access
    Review
    An overview of immune checkpoint inhibitors in breast cancer
    Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-nega...
    Federica Miglietta ... Nicla La Verde
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:452-472
    DOI: https://doi.org/10.37349/etat.2020.00029
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:189
    Download:7
    Times Cited: 0
    Open Access
    Review
    Circulating biomarkers in malignant pleural mesothelioma
    Malignant pleural mesothelioma (MPM) is an aggressive tumor strictly connected to asbestos exposure. Prognosis is dismal as diagnosis commonly occurs in advanced stage. Radiological screenings have ...
    Giuseppe Viscardi ... Giulia Galli
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:434-451
    DOI: https://doi.org/10.37349/etat.2020.00028
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:250
    Download:14
    Times Cited: 0
    Open Access
    Letter to the Editor
    Is hyperprogressive disease a specific phenomenom of immunotherapy?
    Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particula...
    Marta Brambilla ... Mario Occhipinti
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:427-433
    DOI: https://doi.org/10.37349/etat.2020.00027
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:186
    Download:3
    Times Cited: 0
    Open Access
    Review
    An overview of the potential anticancer properties of cardamonin
    Cancer is one of the leading causes of mortality, contributing to 9.6 million deaths globally in 2018 alone. Although several cancer treatments exist, they are often associated with severe side effe...
    Shanaya Ramchandani ... Manoj Garg
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:413-426
    DOI: https://doi.org/10.37349/etat.2020.00026
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    View:220
    Download:4
    Times Cited: 0
    Open Access
    Review
    Targeting transcription factors in cancer drug discovery
    Cancer drug discovery is currently dominated by clinical trials or clinical research. Several potential drug candidates have been brought into the pipeline of drug discovery after showing very promi...
    Partha Mitra
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:401-412
    DOI: https://doi.org/10.37349/etat.2020.00025
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    View:190
    Download:17
    Times Cited: 0
    Open Access
    Review
    Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
    Liquid biopsy has emerged as a minimally invasive alternative to tumor tissue analysis for the management of lung cancer patients, especially for epidermal growth factor receptor (EGFR) oncogene add...
    Marialucia Iacovino ... Francesca Sparano
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:391-400
    DOI: https://doi.org/10.37349/etat.2020.00024
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:206
    Download:9
    Times Cited: 0
    Open Access
    Review
    Novel approaches for the rational design of PROTAC linkers
    Proteolysis targeting chimeras (PROTACs) represent a promising class of hetero-bivalent molecules that facilitate ubiquitination of a target protein by simultaneously binding and bringing together b...
    Almaz Zagidullin ... Emil Bulatov
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381-390
    DOI: https://doi.org/10.37349/etat.2020.00023
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:469
    Download:28
    Times Cited: 0
    Open Access
    Review
    Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer
    Cancer is one of the most dreadful diseases in the world with a mortality of 9.6 million annually. Despite the advances in diagnosis and treatment during the last couple of decades, it still remains...
    Sosmitha Girisa ... Ajaikumar B. Kunnumakkara
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:313-342
    DOI: https://doi.org/10.37349/etat.2020.00019
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    View:252
    Download:14
    Times Cited: 0
    Open Access
    Case Report
    Pseudoprogression in lung cancer: a case report
    Immunotherapy dramatically changed the management of several malignancies including non-small cell lung cancer (NSCLC). Since immune checkpoint inhibitors have a different mechanism of action from c...
    Giulia Meoni ... Angela Stefania Ribecco
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:372-380
    DOI: https://doi.org/10.37349/etat.2020.00022
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:247
    Download:8
    Times Cited: 0
    Open Access
    Original Article
    Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer
    Aim: Tamoxifen (TAM) resistance remains a clinical issue in breast cancer. The authors previously reported that 15-hydroxyprostaglandin dehydrogenase (HPGD) was significantly downregulated in tamox...
    Milene Volpato ... Valerie Speirs
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:355-371
    DOI: https://doi.org/10.37349/etat.2020.00021
    View:492
    Download:17
    Times Cited: 0
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead” ...
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273-312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:1799
    Download:278
    Open Access
    Review
    Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers
    Lung cancer is still one of the main causes of cancer-related death, together with prostate and colorectal cancers in males and breast and colorectal cancers in females. The prognosis for non-small ...
    Giovanni Vicidomini ... Mario Santini
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:343-354
    DOI: https://doi.org/10.37349/etat.2020.00020
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:312
    Download:11
    Times Cited: 0
    Open Access
    Review
    Possible applications of salvianolic acid B against different cancers
    Cancer is the second death causing disease worldwide after cardiovascular abnormalities. The difficulty in treating tumor cells with more precise targeted interventions and recurrence of cancer afte...
    Iram Shahzadi ... Reza Mohammadinejad
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:218-238
    DOI: https://doi.org/10.37349/etat.2020.00014
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    View:433
    Download:8
    Times Cited: 0
    Open Access
    Review
    PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors
    BCL-XL is an anti-apoptotic protein that plays an important role in tumorigenesis, metastasis, and intrinsic or therapy-induced cancer drug resistance. More recently, BCL-XL has also been identified...
    Peiyi Zhang ... Guangrong Zheng
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:259-272
    DOI: https://doi.org/10.37349/etat.2020.00017
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:883
    Download:39
    Times Cited: 0
    Open Access
    Commentary
    Circulating cancer stem cells: an interesting niche to explore
    Federica Papaccio
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:253-258
    DOI: https://doi.org/10.37349/etat.2020.00016
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:536
    Download:15
    Times Cited: 0
    Open Access
    Review
    Future directions and management of liquid biopsy in non-small cell lung cancer
    Lung cancer represents the world’s most common cause of cancer death. In recent years, we moved from a generic therapeutic strategy to a personalized approach, based on the molecular char...
    Alessia Maria Cossu ... Marco Bocchetti
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:239-252
    DOI: https://doi.org/10.37349/etat.2020.00015
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:655
    Download:13
    Times Cited: 0
    Open Access
    Review
    A brief overview of antitumoral actions of bruceine D
    Cancer remains the second leading cause of mortality globally. In combating cancer, conventional chemotherapy and/or radiotherapy are administered as first-line therapy. However, these are usually a...
    Zi Wayne Sin ... Manoj Garg
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:200-217
    DOI: https://doi.org/10.37349/etat.2020.00013
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    View:552
    Download:21
    Times Cited: 0
    Open Access
    Review
    Role of liquid biopsy for thoracic cancers immunotherapy
    Immunotherapy has shifted the therapeutic landscape in thoracic cancers. However, assessment of biomarkers for patient selection and disease monitoring remain challenging, especially considering the...
    Raimondo Di Liello ... Paloma Martín-Martorell
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:183-199
    DOI: https://doi.org/10.37349/etat.2020.00012
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:925
    Download:15
    Times Cited: 0
    Open Access
    Review
    Integration of PARP-inhibitors in ovarian cancer therapy
    Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting....
    Antonella Pietragalla ... Gennaro Daniele
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:171-182
    DOI: https://doi.org/10.37349/etat.2020.00011
    View:543
    Download:13
    Open Access
    Review
    An overview of the anti-cancer actions of Tanshinones, derived from Salvia miltiorrhiza (Danshen)
    Tanshinone is a herbal medicinal compound described in Chinese medicine, extracted from the roots of Salvia miltiorrhiza (Danshen). This family of compounds, including Tanshinone IIA and Tanshinone...
    Irum Naz ... Kwang Seok Ahn
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:153-170
    DOI: https://doi.org/10.37349/etat.2020.00010
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    View:841
    Download:29
    Times Cited: 0
    Open Access
    Review
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell ...
    Rachael Arthur ... Graham Packham
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131-152
    DOI: https://doi.org/10.37349/etat.2020.00009
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:1842
    Download:109
    Open Access
    Review
    Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
    Several preclinical studies suggested a potential benefit from combined treatment with inhibitors of epidermal growth factor receptor (EGFR) and angiogenesis, both effective in patients with advance...
    Giuliano Palumbo ... Alessandro Morabito
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:117-130
    DOI: https://doi.org/10.37349/etat.2020.00008
    View:696
    Download:26
    Times Cited: 0
    Open Access
    Case Report
    Multiple adverse drug reactions during all-trans retinoic acid treatment for acute promyelocytic leukemia: differentiation syndrome, bradycardia, intestinal necrosis
    All-trans retinoic acid (ATRA) induces complete remission in a high proportion of acute promyelocytic leukemia (APL). Nevertheless it is be associated with adverse drug reactions that might be life-...
    Valeria Ferla ... Nicola Stefano Fracchiolla
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:109-116
    DOI: https://doi.org/10.37349/etat.2020.00007
    View:617
    Download:3
    Times Cited: 0
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi...
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71-100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:2033
    Download:126
    Open Access
    Original Article
    Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients
    Aim: Single biomarker diagnostic test of BRAFV600 locus in metastatic melanoma is mandatory for treatment decision; however, multiple-gene based techniques, such as targeted next-generation sequenc ...
    Paola Castillo ... Cristina Teixido
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:101-108
    DOI: https://doi.org/10.37349/etat.2020.00006
    View:714
    Download:21
    Times Cited: 0
    Open Access
    Review
    Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma
    Colorectal carcinoma (CRC) is an heterogeneous disease in which different genetic alterations play a role in its pathogenesis and progression and offer potential for therapeutic intervention. The re...
    Anna Maria Rachiglio ... Nicola Normanno
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:53-70
    DOI: https://doi.org/10.37349/etat.2020.00004
    View:1414
    Download:62
    Times Cited: 0
    Open Access
    Review
    Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer
    The Fanconi anaemia (FA) pathway is an important mechanism for cellular DNA damage repair, which functions to remove toxic DNA interstrand crosslinks. This is particularly relevant in the context of...
    Sarah J Taylor ... Simon P Langdon
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:26-52
    DOI: https://doi.org/10.37349/etat.2020.00003
    View:1569
    Download:61
    Times Cited: 0
    Open Access
    Review
    Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms
    Cancer development is frequently associated with dysregulation of mRNA translation to enhance both increased global protein synthesis and translation of specific mRNAs encoding oncoproteins. Thus, t...
    Joe Taylor ... Graham Packham
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:3-25
    DOI: https://doi.org/10.37349/etat.2020.00002
    View:1534
    Download:63
    Times Cited: 0
    Open Access
    Editorial
    Exploration of Targeted Anti-tumor Therapy: a contribution to the development of targeted therapies
    Nicola Normanno, Graham Packham
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:1-2
    DOI: https://doi.org/10.37349/etat.2020.00001
    View:293
    Download:5
    Times Cited: 0